TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04681625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) with suppressive urgency technique
Description: Pelvic floor muscle training with suppressive urgency technique:~1. Education about proper urination training in the period without pathological urgency.~2. Education about conscious urgency suppression through PFMT - suppressive urgency technique.~3. Education on the principle and effect of PFMT.~4. Exercises of varying intensity of pelvic floor muscles in different positions.~5. Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with suppressive urgency technique
Description: Pelvic floor muscle training with suppressive urgency technique:~1. Education about proper urination training in the period without pathological urgency.~2. Education about conscious urgency suppression through PFMT - suppressive urgency technique.~3. Education on the principle and effect of PFMT.~4. Exercises of varying intensity of pelvic floor muscles in different positions.~5. Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day.
Study: NCT04965389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Oral Solution
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Oral Solution
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Oral Solution
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Oral Solution
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BMS-986177 Solution for Infusion
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BMS-986177 Solution for Infusion
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BMS-986177 Solution for Infusion
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BMS-986177 Solution for Infusion
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Spray-dried Dispersion Capsules
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Spray-dried Dispersion Capsules
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Spray-dried Dispersion Capsules
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Spray-dried Dispersion Capsules
Description: Specified dose on specified days
Study: NCT06090682

Intervention type: DEVICE
Intervention: Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)
Description: We observed the changes in cognitive function of patients before and after different brain stimulation treatments, and further compared the effects of different brain stimulation treatments on cognitive function of PD patients and the related mechanisms according to whether DBS surgery was performed or TMS therapy was given only according to the surgical indications.
Study: NCT05965349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Mind, Healthy Living
Description: A telephone, 8-week MBCT workshop series including: (1) learning mindfulness skills; (2) practicing mindfulness skills in class and at home; and (3) dialogue and inquiry.
Study: NCT05356182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Control diet consisting of 20% protein, intervention diet consisting of 10% protein
Study: NCT05471635

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
Study: NCT04880538

Intervention type: PROCEDURE
Intervention: Endoscopic procedure
Description: Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.

Intervention type: PROCEDURE
Intervention: Endoscopic procedure
Description: Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.
Study: NCT04996680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training
Description: This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardised low load strength training
Description: This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training
Description: This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
Study: NCT05658406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: infusion of 15 mL/kg/hour Ringer's lactate intraoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: infusion of 10 mL/kg/hour Ringer's lactate intraoperative .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: infusion of 6 mL/kg/hour Ringer's lactate intraoperative .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
Study: NCT04650958

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
Study: NCT05970744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/Flu-01E low dose
Description: Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/Flu-01E high dose
Description: Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/Flu-01E high dose
Description: Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single intranasal injection of Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single intranasal injection of Placebo
Study: NCT06170372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 ppm Nitric Oxide
Description: NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
Study: NCT05791812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home-based transcranial direct current stimulation (tDCS)
Description: 2mA of tDCS for 20 min every weekday for six weeks
Study: NCT06170372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 ppm Nitric Oxide
Description: NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham treatment
Description: Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham treatment
Description: Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
Study: NCT05608317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALLEVYN Non-Adhesive
Description: ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction.~ALLEVYN Non-Adhesive consists of the following layers:~* Breathable top film~* Highly absorbent foam core~* Non-adhesive wound contact layer
Study: NCT05790447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: loading dose with thymalfasin based on the amounts of T lymphocyte

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: hypofractionated radiotherapy/SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor
Description: The PD-1/PD-L1 inhibitors are used within one week after radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: subcutaneous injection daily for 7 consecutive days
Study: NCT04812327

Intervention type: DIAGNOSTIC_TEST
Intervention: BD Veritor Plus System for Rapid Detection of SARS CoV-2
Description: Nasal Sawb for the conduct of the Veritor Antigen Test

Intervention type: DIAGNOSTIC_TEST
Intervention: rt-PCR
Description: Nasopharyngeal Swab for the conduct of a rt-PCR
Study: NCT05425433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored serial casting intercention
Description: Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
Study: NCT04722237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy (ACT) is an evidence-based psychological therapy that has been used to improve physical and mental health among adults with health conditions, including cancer (Graham, Gouick, Krahe, \& Gillanders, 2016). It fosters engagement with, rather than avoidance of, painful experiences, to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing problems.
Study: NCT04920617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SC injection on D7 and D28, then every 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SC injection on D7 and D28, then every 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPA
Description: 50 mg twice daily, week on then week off
Study: NCT04812327

Intervention type: DIAGNOSTIC_TEST
Intervention: viral culture
Description: Nasopharyngeal Swab for the conduct of viral culture
Study: NCT06554860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular Blackburn stabilization plus exercise
Description: scapular Blackburn stabilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF plus Exercise
Description: PNF plus Exercise

Intervention type: OTHER
Group type: OTHER
Intervention: exercise only
Description: Exercise only
Study: NCT05752513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Late bladder dissection
Description: The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: early bladder dissection
Description: The bladder dissection is early as in classic cesarean hysterectomy
Study: NCT05717751

Intervention type: PROCEDURE
Intervention: surgical staging
Description: para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
Study: NCT05979324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABAStroke Digital Therapeutics
Description: The total time of the study is 30 weeks in total, i.e. 15 weeks of patient recruitment and then a maximum of another 15 weeks until the end of the observation of the last patient. Within 2 weeks from the last patient, the last Monitor's visit will be performed to close the study. The patient will use the ABAStroke application for a maximum of 91 days (the minimum time is 28 days) and standard therapy, including rehabilitation (as recommended by researchers or other physicians rehabilitating a patient after a stroke).
Study: NCT05483335

Intervention type: OTHER
Intervention: No intervention but assessing for burnout syndrome in all group
Description: Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
Study: NCT06022367

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head Turn Activation Technique
Description: Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head Turn Activation Technique
Description: Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head Raise Activation Technique
Description: Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head Raise Activation Technique
Description: Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
Study: NCT06598293

Intervention type: BEHAVIORAL
Intervention: PRO-CTCAE, Pain NRS
Description: The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a PROM developed to systematically and objectively reflect patients' experiences and perceptions of therapeutic drugs in toxicity evaluation and adverse event reporting. PRO-CTCAE can be used to monitor patients' symptoms and side effects, support therapeutic decision-making, facilitate communication among medical staff, implement patient-centred care, and screen for health conditions.
Study: NCT06616454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group - Time restricted feeding
Description: Participants will be applied with an ad libitum nutrition plan between 10:00-18:00.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group - Time restricted feeding
Description: Participants will be applied with an ad libitum nutrition plan between 10:00-18:00.
Study: NCT06689722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chiropractic
Description: Chiropractic practice was applied using the diversified technique, which is one of the types of chiropractic techniques.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: The patient was asked if he/she had any pain or other complaints during the trial mobilization. High-velocity, low-amplitude impulses were applied to the inferior and lateral directions for patients who did not describe any complaints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergonomics
Description: Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ergonomics
Description: Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ergonomics
Description: Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa
Study: NCT05336305

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Polydextrose
Description: Administration of 3g polydextrose per day, for 2 months
Study: NCT05619393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobilie Bi-planar X-ray Imaging system
Description: on the Mobilie Bi-planar X-ray Imaging system, images are acquired for three movements: walking, downhill walking, and squat
Study: NCT05336305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: Administration of 3g polydextrose per day, for 2 months
Study: NCT05311761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogMe Personal Assistant (PA)
Description: Twice a day, in the morning and evening, the electronic tablet with the CogMe PA will be given to the patient by the research assistant. Patients will be asked to respond to a short question and answer (Q\&A) session of approximately 5-10 minutes duration. This intervention will continue throughout the hospitalization period, estimated at approximately 5 days.
Study: NCT05407506

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: THYROID AI
Description: thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
Study: NCT05057052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab plus regorafenib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be initiated on day 14 after cryoablation. Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: US/CT-guided Percutaneous Cryoablation
Description: Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
Study: NCT04681651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia
Description: Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham Normobaric Hyperoxia
Description: For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endovascular Thrombectomy
Description: EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy
Description: EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.